I am saying that, that period of time would have given Goshen, Abbott and Biocurex ample time to improve, progress and integrate the technology. We should see many positive press releases, and maybe even some independent studies regarding the recaf technology, during this time, not the least of which being the December 2007 payment!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.